Ashfield and Huntsworth unite their full suite of advisory, medical, marketing, communications and patient and stakeholder engagement services to create Inizio, a strategic partner to health and life science companies throughout the life cycle of their drug products.
Posts
Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them.
Lumanity today announced the acquisition of Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life. Lumanity CEO Jon Williams says, “We look forward to working with our new colleagues to define and build market-leading, patient-centered research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”
Evotec SE is on a deal-making spree. The company just inked another contract, this time with Janssen Pharmaceutical that showcases Evotec’s end-to-end integrated drug discovery and development platform.
Leaderboard Branding, a Fingerpaint company – the fast-growing global naming and branding firm that delivers strategic insights and world-class creativity to biopharma and healthcare companies as early as clinical phase 1 – announced the hiring of Max Straka, PharmD, FISMP, a former FDA Division of Medication Error Prevention and Analysis (DMEPA) safety evaluator. As a Director of Leaderboard Branding’s Drug Safety Division, Dr. Straka adds to the broad experience of global leaders and innovators in this important area of drug development.